Theravance and Janssen to Advance TD-1473 for Treatment of Inflammatory Bowel Diseases

Theravance and Janssen to Advance TD-1473 for Treatment of Inflammatory Bowel Diseases
Theravance Biopharma Ireland Limited, a Theravance Biopharma subsidiary, and Janssen Biotech have joined forces to develop and commercialize the investigational therapy TD-1473 as a treatment for inflammatory bowel diseases (IBDs) such as Crohn’s disease and ulcerative colitis. TD-1473 is
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *